Analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to announce $127.57 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for GW Pharmaceuticals PLC-'s earnings. The lowest sales estimate is $122.69 million and the highest is $133.80 million. GW Pharmaceuticals PLC- posted sales of $90.97 million in the same quarter last year, which would indicate a positive year over year growth rate of 40.2%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 3rd.
On average, analysts expect that GW Pharmaceuticals PLC- will report full-year sales of $510.28 million for the current financial year, with estimates ranging from $498.80 million to $522.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $729.26 million, with estimates ranging from $664.50 million to $801.17 million. Zacks' sales averages are an average based on a survey of research firms that cover GW Pharmaceuticals PLC-.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.02. GW Pharmaceuticals PLC- had a negative return on equity of 7.71% and a negative net margin of 12.56%. The business had revenue of $121.30 million during the quarter, compared to the consensus estimate of $94.57 million. During the same period in the previous year, the business earned $0.21 EPS. The business's quarterly revenue was up 68.4% on a year-over-year basis.
Several research firms have commented on GWPH. Evercore ISI upped their price objective on GW Pharmaceuticals PLC- from $250.00 to $275.00 and gave the company an "outperform" rating in a research note on Tuesday, June 30th. HC Wainwright upped their price objective on GW Pharmaceuticals PLC- from $161.00 to $164.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Goldman Sachs Group set a $271.00 price objective on GW Pharmaceuticals PLC- and gave the company an "in-line" rating in a research note on Friday, August 7th. Raymond James began coverage on GW Pharmaceuticals PLC- in a research note on Monday, August 24th. They set a "market perform" rating for the company. Finally, TheStreet downgraded GW Pharmaceuticals PLC- from a "c-" rating to a "d+" rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the company. The company has an average rating of "Buy" and a consensus price target of $180.69.
GW Pharmaceuticals PLC- stock opened at $99.50 on Tuesday. The stock has a 50-day simple moving average of $104.04 and a 200-day simple moving average of $110.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.96 and a current ratio of 5.80. The company has a market capitalization of $3.09 billion, a P/E ratio of -54.08 and a beta of 1.78. GW Pharmaceuticals PLC- has a fifty-two week low of $67.98 and a fifty-two week high of $141.98.
In related news, insider Douglas B. Snyder sold 24,000 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.40, for a total value of $225,600.00. Following the sale, the insider now owns 122,364 shares in the company, valued at approximately $1,150,221.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Volker Knappertz sold 6,000 shares of the company's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $11.42, for a total value of $68,520.00. Following the completion of the sale, the insider now owns 53,940 shares in the company, valued at approximately $615,994.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,804 shares of company stock worth $463,722. Insiders own 3.10% of the company's stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth approximately $1,670,000. Laidlaw Wealth Management LLC acquired a new stake in GW Pharmaceuticals PLC- during the 2nd quarter valued at $458,000. Pinnacle Associates Ltd. acquired a new stake in GW Pharmaceuticals PLC- during the 2nd quarter valued at $266,000. Cubist Systematic Strategies LLC grew its holdings in GW Pharmaceuticals PLC- by 142.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 7,911 shares of the biopharmaceutical company's stock valued at $971,000 after buying an additional 4,645 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in GW Pharmaceuticals PLC- by 583.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 514,806 shares of the biopharmaceutical company's stock valued at $63,177,000 after buying an additional 439,523 shares during the last quarter. Institutional investors and hedge funds own 80.52% of the company's stock.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
See Also: What can cause a stock to outperform?
Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Analysts Hate These 12 Stocks
When a single Wall Street analyst downgrades one of your stocks, you might think they are just having a bad day or have an incorrect investment thesis. One downgrade typically won't have a significant impact on the price of one of your stocks, but what if analysts repeatedly downgraded a company over the last 30, 60, or 90 days? You would know something is seriously wrong.
Today, we invite you to take a free exclusive look at our up-to-the-minute list of 12 "Most Downgraded" stocks. These are true strong sell stocks. Analysts are abandoning them in droves and issuing rare downgrades and sell ratings. If any of these stocks are lurking around in your portfolio, seriously consider whether or not they still belong in your portfolio.
View the "Analysts Hate These 12 Stocks".